Higher levels of Lp(a) are also associated with deep vein thrombosis and pulmonary embolism according to this retrospective cohort study.
|Articles|September 16, 2008
- March15 2005
- Volume 12
- Issue 5
Little Stock Steps
Author(s)Grace K. Henry & Michael Sheehan
Advertisement
If you're looking to play fairy godparent,but can't give your relations the redcarpet treatment just yet, there is a way tomake small, steady stock investmentswithout paying disproportionately highfees. Physician-investors can invest smallamounts in fractional shares of stocksthrough ShareBuilder (866-747-2537;www.sharebuilder.com). There are nominimum balance requirements for abasic account, and you can invest once,weekly, or monthly. The account costs $4per investment for automatically recurringinvestments. Real-time trades are$15.95 per trade. ShareBuilder also hasaccounts with a monthly charge inexchange for a limited number of freeautomatic investments and lower fees forreal-time trades.
Advertisement
Related to this article
Donald Cutlip, MD, discusses the sirolimus balloon’s approval and its role in clinical practice for patients with ISR.
Ochsner Transplant Institute director discusses liver transplant care, robotic kidney transplant, organ preservation, and access gaps.
Mirum's antibody led to virologic response and ALT normalization in up to 56% of patients at week 24, vs 0% with delayed treatment.
Murad Alam, MD, and Elizabeth Kiracofe, MD, discuss how reimbursement, coverage, and advocacy shape dermatology access for patients with skin of color.
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
2
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
3
Brelovitug Meets Primary Endpoint in Phase 3 AZURE-1 Hepatitis Delta Trial
4
Skin of Color Savvy: Reimbursement, Coverage, and Care Gaps for Patients With Skin of Color
5